JP2010522152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522152A5 JP2010522152A5 JP2009554083A JP2009554083A JP2010522152A5 JP 2010522152 A5 JP2010522152 A5 JP 2010522152A5 JP 2009554083 A JP2009554083 A JP 2009554083A JP 2009554083 A JP2009554083 A JP 2009554083A JP 2010522152 A5 JP2010522152 A5 JP 2010522152A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- bone
- compound according
- ring
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 14
- 206010061218 Inflammation Diseases 0.000 claims 12
- 230000004054 inflammatory process Effects 0.000 claims 12
- 206010065687 Bone loss Diseases 0.000 claims 10
- 230000004913 activation Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000020084 Bone disease Diseases 0.000 claims 6
- 206010023203 Joint destruction Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 210000002997 osteoclast Anatomy 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 208000006386 Bone Resorption Diseases 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 208000027067 Paget disease of bone Diseases 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 208000016738 bone Paget disease Diseases 0.000 claims 4
- 230000024279 bone resorption Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 239000004579 marble Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 0 *N([Al]I*)S([Al][Al]I)(=O)=O Chemical compound *N([Al]I*)S([Al][Al]I)(=O)=O 0.000 description 12
- SPTJCYWEGIYIJX-UCNYIJHQSA-N C/C=C(/C1C=CC(S(/N=C2\C=CC=C(CCCO)C2)(=O)=O)=CC=C1)\C(\F)=C/C(F)=C Chemical compound C/C=C(/C1C=CC(S(/N=C2\C=CC=C(CCCO)C2)(=O)=O)=CC=C1)\C(\F)=C/C(F)=C SPTJCYWEGIYIJX-UCNYIJHQSA-N 0.000 description 1
- IRADXTURDJBIPE-UHFFFAOYSA-N C=C(C1)C(c(ccc(Cl)c2)c2Cl)=CC=C1S(Nc1cc(CCO)ccc1)(=O)=[U] Chemical compound C=C(C1)C(c(ccc(Cl)c2)c2Cl)=CC=C1S(Nc1cc(CCO)ccc1)(=O)=[U] IRADXTURDJBIPE-UHFFFAOYSA-N 0.000 description 1
- YUFKSFFAHGRLQJ-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc1)ccc1S(Nc1cccc(CO)c1)(=N)=O Chemical compound Cc(cc1)ccc1-c(cc1)ccc1S(Nc1cccc(CO)c1)(=N)=O YUFKSFFAHGRLQJ-UHFFFAOYSA-N 0.000 description 1
- YOGYLSSOGBIQMI-UHFFFAOYSA-N OCc(cc1)c(CO)cc1NS(c(cc1)ccc1-c(ccc(Cl)c1)c1Cl)(=O)=O Chemical compound OCc(cc1)c(CO)cc1NS(c(cc1)ccc1-c(ccc(Cl)c1)c1Cl)(=O)=O YOGYLSSOGBIQMI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0705400.0A GB0705400D0 (en) | 2007-03-21 | 2007-03-21 | Therapeutic compounds andm their use |
| GB0705400.0 | 2007-03-21 | ||
| PCT/GB2008/000989 WO2008114022A1 (en) | 2007-03-21 | 2008-03-20 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522152A JP2010522152A (ja) | 2010-07-01 |
| JP2010522152A5 true JP2010522152A5 (cg-RX-API-DMAC7.html) | 2011-05-06 |
| JP5450105B2 JP5450105B2 (ja) | 2014-03-26 |
Family
ID=38024559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554083A Active JP5450105B2 (ja) | 2007-03-21 | 2008-03-20 | ビフェニル−４−イル−スルホン酸アリールアミド及びその治療剤としての使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8524778B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2137141B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5450105B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2681320C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2137141T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2561163T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0705400D0 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20160183T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE028656T2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2137141T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008114022A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| US9233946B2 (en) | 2010-09-17 | 2016-01-12 | Kancera Ab | Sulfonamide compounds |
| US10941109B2 (en) | 2011-06-13 | 2021-03-09 | Ergon Pharmaceuticals Llc | Compositions and methods of treatment using a BCAT1 inhibitor |
| WO2012173987A2 (en) | 2011-06-13 | 2012-12-20 | Ergon Pharmaceuticals Llc | Methods of treatment using a bcat1 inhibitor |
| US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| EP2794009B1 (en) * | 2011-12-22 | 2017-08-30 | Kancera AB | Bisarylsulfonamides useful in the treatment of inflammation and cancer |
| MX2015006844A (es) * | 2012-12-10 | 2015-09-16 | Hoffmann La Roche | Derivados de bencilsulfonamida como moduladores del receptor huerfano relacionado al receptor de retinoide (rorc). |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| EP3046561B1 (en) | 2013-09-20 | 2023-02-22 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Compounds for treating prostate cancer |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| WO2018146129A1 (en) | 2017-02-07 | 2018-08-16 | Orthogenics As | Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening |
| WO2020097408A1 (en) * | 2018-11-09 | 2020-05-14 | Nimbus Artemis, Inc. | Acly inhibitors and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| GB2001307A (en) * | 1977-07-01 | 1979-01-31 | American Cyanamid Co | Sulphonamide blood complement inhibitors |
| US4119784A (en) * | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| AU1118097A (en) | 1995-10-30 | 1997-05-22 | Smithkline Beecham Corporation | Protease inhibitors |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2421797A (en) | 1996-03-15 | 1997-10-01 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| PL331338A1 (en) | 1996-07-22 | 1999-07-05 | Monsanto Co | Thiosulphonamidic metaloprotease inhibitors |
| AU731737B2 (en) | 1996-10-16 | 2001-04-05 | Wyeth Holdings Corporation | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| AU5362998A (en) | 1996-11-27 | 1998-06-22 | Du Pont Pharmaceuticals Company | Novel integrin receptor antagonists |
| AU6780398A (en) | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
| HUP0002951A3 (en) | 1997-05-08 | 2002-10-28 | Smithkline Beecham Corp | Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| DE59802394D1 (de) | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| AP1269A (en) | 1998-01-23 | 2004-04-03 | Aventis Pharma Deutschland Gmbh | Novel salfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion. |
| EP1053226A1 (en) | 1998-02-04 | 2000-11-22 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| WO2001070720A2 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| JP2004535390A (ja) * | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| NZ541950A (en) | 2001-08-09 | 2007-02-23 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| GB0126157D0 (en) * | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| AU2003221160A1 (en) | 2002-03-27 | 2003-10-08 | Shionogi And Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
| ATE469903T1 (de) | 2002-09-04 | 2010-06-15 | Schering Corp | Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine |
| DE10251170A1 (de) * | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| DK1638544T3 (da) | 2003-05-07 | 2008-03-31 | Univ Aberdeen | Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| EP1696915A1 (en) | 2003-12-19 | 2006-09-06 | Pfizer, Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| GB0405193D0 (en) * | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| EP1756025A1 (en) | 2004-05-05 | 2007-02-28 | Novo Nordisk A/S | Sulfonamide derivatives |
| GB0412553D0 (en) * | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) * | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| KR20080016649A (ko) | 2005-06-16 | 2008-02-21 | 화이자 인코포레이티드 | Ｎ-(피리딘-2-일)-술폰아미드 유도체 |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) * | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| EP1984344B1 (en) | 2005-12-29 | 2012-09-26 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
-
2007
- 2007-03-21 GB GBGB0705400.0A patent/GB0705400D0/en not_active Ceased
-
2008
- 2008-03-20 WO PCT/GB2008/000989 patent/WO2008114022A1/en not_active Ceased
- 2008-03-20 HU HUE08718826A patent/HUE028656T2/en unknown
- 2008-03-20 DK DK08718826.4T patent/DK2137141T3/en active
- 2008-03-20 US US12/531,732 patent/US8524778B2/en active Active
- 2008-03-20 JP JP2009554083A patent/JP5450105B2/ja active Active
- 2008-03-20 CA CA2681320A patent/CA2681320C/en active Active
- 2008-03-20 EP EP08718826.4A patent/EP2137141B1/en active Active
- 2008-03-20 HR HRP20160183T patent/HRP20160183T1/hr unknown
- 2008-03-20 SI SI200831582T patent/SI2137141T1/sl unknown
- 2008-03-20 ES ES08718826.4T patent/ES2561163T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522152A5 (cg-RX-API-DMAC7.html) | ||
| JP3880041B2 (ja) | ６−メルカプト−シクロデキストリン誘導体：薬物誘導神経筋遮断回復薬 | |
| HRP20160183T1 (hr) | Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava | |
| TW199896B (cg-RX-API-DMAC7.html) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| JP2008545652A5 (cg-RX-API-DMAC7.html) | ||
| JP2016193934A5 (cg-RX-API-DMAC7.html) | ||
| JP2020510054A5 (cg-RX-API-DMAC7.html) | ||
| JP2003506491A5 (cg-RX-API-DMAC7.html) | ||
| JP2013536807A5 (cg-RX-API-DMAC7.html) | ||
| JP2002522443A5 (cg-RX-API-DMAC7.html) | ||
| JP2007508238A5 (cg-RX-API-DMAC7.html) | ||
| JP2005533106A5 (cg-RX-API-DMAC7.html) | ||
| JP2701952B2 (ja) | Ｎ‐複素環プロピリデン‐１，１‐ビスホスホン酸、その製法および薬剤組成物 | |
| JPH07507317A (ja) | 異常なカルシウムおよびホスフェート代謝を治療するためのチオ置換窒素含有複素環式ホスホネート化合物 | |
| ES2533007T3 (es) | Compuesto de benzoacepina soluble en agua y su composición farmacéutica | |
| CA2831713C (fr) | Derives d'acide hydroxybisphosphonique bifonctionnels et leur utilisation dans la vectorisation de molecules d'interet therapeutique ou diagnostique | |
| JP2002531441A5 (cg-RX-API-DMAC7.html) | ||
| ES2945062T3 (es) | Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer | |
| JPWO2019031470A1 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP3883137B2 (ja) | ピリジルビスホスホン酸エステルよりなる治療用活性薬剤 | |
| JPH07507315A (ja) | カルシウムおよびホスフェート代謝異常治療用含硫ホスホネート化合物 | |
| RU2003122189A (ru) | Сульфамидотиенопиримидины | |
| KR102285724B1 (ko) | Dna 단편 혼합물 및 히알루론산을 포함하는 연골 재생용 조성물 | |
| US7455856B2 (en) | Lipid-derivatized bisphosphonic acid |